Domperidone

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Choi, 2013	Korea Not specified	First trimester pregnant women who were referred to the Korean Motherisk Program for prenatal risk counselling.	Pregnant women treated with domperidone for controlling gastrointestinal symptoms.	unexposed (general population or NOS) Pregnant women who were not exposed to any other teratogenic medication.	120 / 212
Cottin (Control exposed to other treatments), 2015	France 1995 - 2014	Pregnant women who called TIS to be counselled about teratogenicity.	Pregnant women exposed to domperidone within 4 to 12 weeks after the last menstrual period and not exposed to any other antiemetic drug during embryogenesis.	exposed to other treatment, sick Pregnant women who were taking other antiemetic drugs (metoclopramide or doxylamine).	124 / 97	Raw data provided by personal communication of the authors.
Cottin (Controls unexposed, disease free), 2015	France 1995 - 2014	Pregnant women who called TIS to be counselled about teratogenicity	Pregnant women exposed to domperidone within 4 to 12 weeks after the last menstrual period and not exposed to any other antiemetic drug during embryogenesis.	unexposed, disease free Pregnant women who were counselled after a non-teratogenic exposure during the same period	124 / 248	Raw data provided by personal communication of the authors.

Study	Country Study period	Case	Control	Sample size	Rmk
Fejzo, 2015	USA 2007 - 2011	Children exposed to hyperemesis gravidarum (HG) with neurodevelopmental delay.	Children exposed to hyperemesis gravidarum (HG) with a good outcome.	138 / 174	Main analysis: case control related to the impact of the HG illness (treated or not) on child outcomes. Then impact of 37 medications/treatments (1st and/or 2nd trimester) on child outcome was investigated (none was significantly associated with delay).
Fejzo, 2013	USA 2007 - 2011	Pregnant women with hyperemesis gravidarum (HG) who have negative outcomes (birth weight less than 10%, perinatal mortality, and/or preterm birth (<37 weeks)).	Pregnant women with hyperemesis gravidarum (HG) who have positive outcomes.	43 / 211	Comparison of use of various medications/treatments in the two groups (43 HG participants with an adverse outcome compared to 211 HG participants with a good outcome).